ClinicalTrials.gg
RecruitingNCT07070401Updated Jul 17, 2025

The Use of AR / VR in Patients Presenting to the ED With Renal Colic

An interventional study of Commercial AR/VR Headset with Calming App and Pharmacologic Standard of Care Alone in Renal Colic and Kidney Stones, Urolithiasis, Hypocitraturia, sponsored by Community Medical Center, Toms River, NJ. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Community Medical Center, Toms River, NJ · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Utilization of VR / AR Calming as an adjunct to pharmacologic pain management for Renal Colic in Emergency Department Patients

Read the detailed description

This study will randomize ED patients presenting for presumed renal colic to either standard pharmacologic pain management alone, or pharmacologic management plus use of an adjunct Virtual / Augmented reality calming application using an off-the-shelf VR/AR Headset.

02

Conditions studied

  • Renal Colic
  • Kidney Stones, Urolithiasis, Hypocitraturia

Keywords

  • Renal Colic
  • Nephrolithiasis
  • Urolithiasis
  • Emergency Department
  • Pain Management
  • Virtual Reality
  • Augmented Reality
  • Audiovisual Stimulation
  • Patient Anxiety
03

In context

Renal Colic

79 studies on the registry are indexed under Renal Colic; 10 are open to participants now.

This study's planned enrollment of 92 is below the median of 118 across 60 interventional studies indexed under Renal Colic.

Browse Renal Colic studies →

Lead sponsor

Community Medical Center, Toms River, NJ is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient self-reported history of nephrolithiasis
  • Subjective history suggesting that current presentation is similar to past presentations of nephrolithiasis (character, quality, location, intensity of pain; previous surgical intervention or lithotripsy)
  • Patients with self-reported moderate to severe pain on the visual pain scale determined as greater than 5/10
  • Normal vital signs (afebrile)
  • Agreeable to as dictated by IRB and local practice
  • No to standard therapy (ie fluids, NSAIDs, opioids, etc.)
  • Compliance with the virtual reality treatment
  • Keeps the headset on for the duration of the experience
  • Understands the instructions

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Pregnant
  • Individuals with chronic pain conditions such as fibromyalgia (chronic pain may confound results, as patients may have higher than baseline pain levels affecting their response to medications)
  • Individuals with severe anxiety or claustrophobia
  • Individuals with severe motion sickness or previous episodes of motion sickness due to VR (those who may not react well to the VR experience)
  • Individuals with \<60 or previous documented diagnosis of CKD as they may not be suitable candidate for traditional analgesia
  • Individuals with previous opioid dependence
  • Requirement of immediate surgery (obstructing calculi with concomitant urinary tract infection)
  • Patients with diagnoses meeting admission criteria (sepsis, MI)
  • Audio/visual impairment (unable to appreciate stimuli provided by the headset)
  • Patients administered opiates as the pain control medication will not be included in final data collection, as opioid administration may result in difficulty consenting and understanding the study protocol / design
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Active comparator
    Standard of Care Pharmacologic Management

    Patients receive standard of care pharmacologic management at the discretion of the treating provider

    Other: Pharmacologic Standard of Care Alone

  • Experimental
    AR Adjunct Plus Standard of Care Pharmacologic Management

    Patients receive adjunct AR Calming App via commercial AR/VR headset in addition to standard of care pharmacologic management at the discretion of the treating provider

    Device: Commercial AR/VR Headset with Calming App

Interventions

  • DeviceCommercial AR/VR Headset with Calming App

    Commercial AR/VR Headset with Calming App in addition to Pharmacologic Standard of Care

  • OtherPharmacologic Standard of Care Alone

    Pharmacologic Standard of Care Alone

06

What researchers measure

Primary outcomes

  1. 60 Minute Pain Level

    Pain Level Change 60 minutes after enrollment, utilizing a 0-10 subjective score

    Time frame: 60 minutes

Secondary outcomes

  1. 30 Minute Pain Level

    Pain Level 30 minutes after enrollment, utilizing a 0-10 subjective score

    Time frame: 30 minutes

  2. 30 Minute Heart Rate

    Change in Heart Rate 30 minutes after enrollment

    Time frame: 30 minutes

  3. 30 Minute Blood Pressure

    Systolic and Diastolic Blood Pressures 30 minutes after enrollment

    Time frame: 30 minutes

  4. 60 Minute Heart Rate

    Change in Heart Rate 60 minutes after enrollment

    Time frame: 60 Minutes

  5. 60 Minute Blood Pressure

    Systolic and Diastolic Blood Pressures 60 minutes after enrollment

    Time frame: 60 minutes

  6. Rescue Analgesia Use

    Requirement for Rescue Analgesia

    Time frame: 4 hours

  7. Rescue Intervention

    Requirement of Specialty Urologic Procedural Intervention for Pain Management (All Cause)

    Time frame: 24 Hours

Other outcomes

  1. Visual Analog Scale for Anxiety

    Anxiety, as measured on a 10 cm line, with 0 being no anxiety, and 10 being worst anxiety patient has experienced, caused by AR Headset, to be measured in the AR Arm only

    Time frame: 60 minutes

  2. Subjective AR Experience

    Likert Scale Response on if patient would use AR headset again, in AR arm only: 1 - Would Never Use Again; 2 - Would Consider Using Again; 3 - Neutral; 4 - Would Definitely Use Again if Offered; 5 - Would Ask to Use It Even if Not Offered

    Time frame: 60 minutes

07

Study locations

1 of 1 sites recruiting
  • Rutgers Robert Wood Johnson Barnabas Health Community Medical Center
    Toms River, New Jersey 08755, United States
    Recruiting
    • Greg Neyman, MD · ContactGregoryMD.Neyman@rwjbh.org · 732.557.3242
    • Chris Delmaestro, DO · Principal investigator
    • Emerson Franke, MD · Sub investigator
08

References and documents

Publications

  • Weynants L, Chys B, D'hulst P, Merckx L, Van Besien J, Tailly T. Virtual reality for pain control during shock wave lithotripsy: a randomized controlled study. World J Urol. 2023 Feb;41(2):589-594. doi: 10.1007/s00345-023-04280-8. Epub 2023 Jan 21. PubMed 36680576 ↗
  • Pourmand A, Davis S, Marchak A, Whiteside T, Sikka N. Virtual Reality as a Clinical Tool for Pain Management. Curr Pain Headache Rep. 2018 Jun 15;22(8):53. doi: 10.1007/s11916-018-0708-2. PubMed 29904806 ↗
  • Mallari B, Spaeth EK, Goh H, Boyd BS. Virtual reality as an analgesic for acute and chronic pain in adults: a systematic review and meta-analysis. J Pain Res. 2019 Jul 3;12:2053-2085. doi: 10.2147/JPR.S200498. eCollection 2019. PubMed 31308733 ↗
  • Gottlieb M, Long B, Koyfman A. The evaluation and management of urolithiasis in the ED: A review of the literature. Am J Emerg Med. 2018 Apr;36(4):699-706. doi: 10.1016/j.ajem.2018.01.003. Epub 2018 Jan 5. PubMed 29321112 ↗
  • Holdgate A, Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ. 2004 Jun 12;328(7453):1401. doi: 10.1136/bmj.38119.581991.55. Epub 2004 Jun 3. PubMed 15178585 ↗
  • Epidemiology of Nephrolithiasis. Course on Advances in Nephrology and Dialysis
  • Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008 Jun;35(2):369-91, vii. doi: 10.1016/j.pop.2008.01.005. PubMed 18486720 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07070401
Lead sponsor
Community Medical Center, Toms River, NJ
Responsible party
Greg Neyman (Research Director, Community Medical Center, Toms River, NJ) — Principal investigator
First posted
Jul 17, 2025
Start date
Apr 1, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Greg Neyman, MD
Contact
GregoryMD.Neyman@rwjbh.org
732.557.3242
Chris Delmaestro, DO
principal investigator · Rutgers RWJBH Community Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion